EHA 2020

The Annual Congress of EHA is a flagship meeting held in a major European city every June— a significant meeting place for haematologists from across the world including Australia. This annual conference encompasses the entire spectrum of haematological studies including Lymphoma and CLL.
On this page:

Due to the massive worldwide impact of the COVID-19 crisis, the 25th Congress of the European Hematology Association (EHA) was replaced by a virtual edition.

Lymphoma Australia was honoured to have the opportunity to interview some of our expert clinicians in Australia who provided their reviews of papers, research, and presentations – and how this relates to Australian patients.

On behalf of the Lymphoma / CLL community we would also like to take this opportunity to thank everyone for their time. Knowledge is power.

EHA 2020 Congress - Aggressive lymphoma updates

EHA 2020 Congress - Indolent lymphoma updates

EHA 2020 Congress - Classical Hodgkin Lymphoma

EHA 2020 Congress - Mantle cell lymphoma & Waldenstrom’s macroglobulinemia highlights

EHA 2020 Congress - ASPEN study for Waldenstrom’s macroglobulinemia

EHA 2020 congress - Long term results from the Gallium study for follicular lymphoma

EHA 2020 congress - Zanubrutinib for Waldenstrom’s macroglobulinemia

Share This

Contact Lymphoma Australia Today!

Please note: Lymphoma Australia staff are only able to reply to emails sent in English language.

For people living in Australia, we can offer a phone translation service. Have your nurse or English speaking relative call us to arrange this.

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.